Imacent 400 mg (Tablet)
Unit Price: ৳ 300.00 (5 x 6: ৳ 9,000.00)
Strip Price: ৳ 1,800.00
Medicine Details
Category | Details |
---|---|
Generic | Imatinib mesylate |
Company | Incepta pharmaceuticals ltd |
Also available as |
Indications
- Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase
- Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy
- Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
- Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
- Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements
- Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown
- Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a fusion kinase
- Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
- Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
- Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST
Pharmacology
- Small molecule protein-tyrosine kinase inhibitor
- Inhibits Bcr-Abl tyrosine kinase and several receptor tyrosine kinases
- Absorption and Distribution details provided
- Metabolism through CYP3A4 enzyme
- Excretion in feces mostly as metabolites
Dosage & Administration
- Adults with Ph+ CML CP: 400 mg/day
- Pediatrics with Ph+ CML CP: 340 mg/m2/day
- Adults with Ph+ ALL: 600 mg/day
- Adults with ASM: 100 mg/day or 400 mg/day
- Imatinib should be taken with a meal and a large glass of water
Interaction
- Agents Inducing CYP3A Metabolism
- Agents Inhibiting CYP3A Metabolism
- Interactions with Drugs Metabolized by CYP3A4
- Interactions with Drugs Metabolized by CYP2D6
Side Effects
- Fluid Retention and Edema
- Hematologic Toxicity
- Congestive Heart Failure and Left Ventricular Dysfunction
- Hepatotoxicity
- Hemorrhage
- Gastrointestinal Disorders
- Hypothyroidism
- Growth Retardation in Children and Adolescents
- Tumor Lysis Syndrome
- Impairments Related to Driving and Using Machinery
- Renal Toxicity
Pregnancy & Lactation
- Use of effective contraception advised for women of childbearing potential
- Limited data on use in pregnant women
- Advice against breastfeeding during treatment
Precautions & Warnings
- Edema and severe fluid retention
- Cytopenias
- Severe congestive heart failure and left ventricular dysfunction
- Severe hepatotoxicity
- Grade 3/4 hemorrhage
- Bullous dermatologic reactions
- Hypothyroidism
- Fetal harm
- Growth retardation in children
- Tumor Lysis Syndrome
- Reports of motor vehicle accidents
- Renal Toxicity
Overdose Effects
- Limited experience with high doses
- Reported effects of overdose in adults and pediatric population
Therapeutic Class
Targeted Cancer Therapy, Tyrosine Kinase Inhibitor
Storage Conditions
Store below 30°C, in a cool and dry place, Keep away from light